• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home StudyGraphics

#VisualAbstract: First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning

byConstance Wu
May 20, 2020
in StudyGraphics
Reading Time: 2 mins read
#VisualAbstract: First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning
Share on FacebookShare on Twitter

1. Following aggressive interventions across China since January 23, 2020, the confirmed case fatality risk in mainland China was 0.98%, five times smaller than that of Hubei, the epicenter of the COVID-19 spread.

 2. Relaxing restrictions and allowing the instantaneous reproduction number to rise above 1, even if restrictions were subsequently tightened, would likely still result in health and economic losses. 

Evidence Rating Level: 3 (Average)

Mainland China has observed 13,415 confirmed cases of COVID-19 and 120 deaths as of March 18, 2020. This is outside the epicenter of the virus outbreak in Hubei province. Massive non-pharmacological interventions were implemented across the country to reduce the spread, including a lockdown of Wuhan since January 23, 2020 along with 16 neighboring cities. This study provided an impact assessment of the severity and transmissibility of COVID-19 during the first wave in four cities (confirmed cases): Beijing (411), Shanghai (337), Shenzhen (417), and Wenzhou (504). Further, a susceptible-infectious-recovered model was used to simulate the potential effects of relaxing the interventions following the first wave. An instantaneous reproduction number (Rt) of COVID-19 was defined as the average number of secondary cases that one primary case could generate and derived from various databases from each city. Rt substantially decreased following the implementation of aggressive measures, keeping it steadily below 1. The confirmed case-fatality risk (cCFR) outside Hubei was 0.98% (95% CI 0.82 to 1.16), though the authors noted substantial heterogeneity across provinces such as Hubei (cCFR 5.91%, 95% CI 5.73 to 6.09) due to variable economies and healthcare resources. A susceptible-infectious-recovered model was used to simulate the potential effects of relaxing the interventions following the first wave. It was found that mainland China is capable of doing so very slowly, such that Rt will not exceed 1. As Rt is a function of time, quick relaxation of interventions or continuation of relaxation when the threshold had been breached resulted in a severe and exponential rise in COVID-19 cases. Relaxation should only be considered when the Rt is consistently <1 and can be kept at that level. Overall, the authors provide a basis upon which other countries with rising cases can learn, including not only aggressive measures to thwart the spread of the virus but very careful and slow relaxation of these interventions when the first wave subsides.

Click to read the study in Lancet

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

The Scan by 2 Minute Medicine®: Fall boosters, mosquitoes, skin awareness, and Hollywood healing

The 2 Minute Medicine Podcast Episode 27

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

Tags: chinaCoronavirusHubeiinstantaneous reproduction number SARS-CoV-2
Previous Post

School-based mental illness curriculum intervention can reduce stigma, increase rates of treatment among youth

Next Post

Atezolizumab-bevacizumab treatment increases survival in unresectable hepatocellular carcinoma

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Fall boosters, mosquitoes, skin awareness, and Hollywood healing

August 28, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 27

November 2, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 6

February 9, 2023
Next Post
Quick Take: Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study

Atezolizumab-bevacizumab treatment increases survival in unresectable hepatocellular carcinoma

Radiological findings of COVID-19 pneumonia in Wuhan, China

RT-PCR results during early SARS-CoV-2 infection course require cautious interpretation

#VisualAbstract: Association of childhood obesity with risk of early all-cause and cause-specific mortality

#VisualAbstract: Association of childhood obesity with risk of early all-cause and cause-specific mortality

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
  • A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality
  • Ecopipam reduces relapse risk in pediatric Tourette syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.